NCT03994601 2026-01-20
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
Clinical Trials
14 trialsNCT04495296 2025-12-19
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT02743494 2025-11-18
CheckMate 577
Bristol-Myers Squibb
Phase 3 Completed
NCT03446040 2025-09-18
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT03459222 2025-04-02
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04270864 2024-10-18
PRIMO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Terminated
NCT02996110 2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2 Completed
NCT03444753 2022-05-23
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
Bristol-Myers Squibb
Phase 1 Terminated
NCT03203876 2022-03-10
A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03792750 2022-02-28
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03661632 2021-11-08
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03745807 2021-10-04
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT03192943 2019-04-01
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
Bristol-Myers Squibb
Phase 1 Completed